Journal article
Experimental and Human Evidence for Lipocalin-2 (Neutrophil Gelatinase-Associated Lipocalin [NGAL]) in the Development of Cardiac Hypertrophy and heart failure
Francine Z Marques, Priscilla R Prestes, Sean G Byars, Scott C Ritchie, Peter Wurtz, Sheila K Patel, Scott A Booth, Indrajeetsinh Rana, Yosuke Minoda, Stuart P Berzins, Claire L Curl, James R Bell, Bryan Wai, Piyush M Srivastava, Antti J Kangas, Pasi Soininen, Saku Ruohonen, Mika Kahonen, Terho Lehtimaki, Emma Raitoharju Show all
Journal of the American Heart Association | WILEY | Published : 2017
Related Projects (1)
Grants
Awarded by National Health & Medical Research Council of Australia
Awarded by National Heart Foundation
Awarded by NHMRC
Awarded by Career Development Fellowship from the National Health & Medical Research Council of Australia
Awarded by Academy of Finland
Awarded by University of Bristol and UK Medical Research Council
Awarded by Turku University Hospital Medical Funds
Funding Acknowledgements
This work was supported by grants from the National Health & Medical Research Council of Australia (project grant APP1034371, APP509252), the National Heart Foundation (project grant G10M5155, GM6368), and the Federation University Australia "Self-sustaining Regions Research and Innovation Initiative," an Australian Government Collaborative Research Network (CRN). Marques is supported by NHMRC (APP1052659) and National Heart Foundation (PF12M6785) co-shared Early Career Fellowships, and a National Heart Foundation Future Leader and Baker Fellowships. Prestes is supported by a Robert HT Smith Fellowship from the Federation University Australia. Patel is supported by a Melbourne University Career Development Fellowship. Inouye was supported by a Career Development Fellowship from the National Health & Medical Research Council of Australia and National Heart Foundation (APP1061435). Byars and Inouye were supported by an NHMRC Project Grant (APP1062227). Wlodek was supported by a National Health & Medical Research Council of Australia Project Grant (APP400003). Salomaa was supported by the Finnish Foundation for Cardiovascular Research. Kettunen was supported by the Academy of Finland (grant 283045). Ala-Korpela receives funds from the University of Bristol and UK Medical Research Council (MC_UU_12013/1). Wurtz was supported by the Novo Nordisk Foundation. The Young Finns Study was financially supported by the Academy of Finland: grants 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland; Kuopio, Tampere, and Turku University Hospital Medical Funds (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation of Cardiovascular Research; Finnish Cultural Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjo Jahnsson Foundation; and Signe and Ane Gyllenberg Foundation. The quantitative serum NMR metabolomics platform and its development was supported by the Academy of Finland, TEKES-the Finnish Funding Agency for Technology and Innovation, Sigrid Juselius Foundation, Novo Nordisk Foundation, Finnish Diabetes Research Foundation, Paavo Nurmi Foundation, and strategic and infrastructural research funding from the University of Oulu, Finland, British Heart Foundation, Wellcome Trust, and Medical Research Council, UK.